Gradalisincis A Privately Held Biotechnology Company Based In Carrolltontexasfounded In 2006The Company Specializes In Developing Personalized Therapeutics For Cancer Treatmentparticularly Through Its Innovative Approach To Cancer Immunotherapygradalis Utilizes Proprietary Bi Shrnai Technology To Create Treatments That Harness The Patient S Immune System To Target Cancer Cells Effectively The Lead Productvigilgemogenovatucel T Is A Personalized Immunotherapy That Stimulates An Immune Response Using The Patient S Own Tumor Cellsit Aims To Enhance The Immune System S Ability To Recognize And Attack Cancer By Decloaking Tumor Clonal Neoantigensvigil Has Shown Promising Results In Clinical Trialsespecially For Ovarian Cancerand Has Received The Fda S Regenerative Medicine Advanced Therapy Designationindicating Its Potential As A Significant Treatment Optiongradalis Continues To Conduct Extensive Clinical Trials To Evaluate Vigil S Efficacy Across Various Tumor Types
